Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | Integrating novel agents into the treatment of multiple myeloma

There is now a rich pipeline of novel agents in clinical trials for the treatment of patients with multiple myeloma. At the 20th Congress of the European Hematology Association (EHA), Pieter Sonneveld, MD, of the Erasmus MC University Cancer Institute, Rotterdam, the Netherlands, discusses the impact of these novel agents in current treatment practices for multiple myeloma.